预约演示
更新于：2025-07-15
Celecoxib
塞来昔布
更新于：2025-07-15
概要
基本信息
简介CELEBREX是一种非甾体抗炎药。Celecoxib具有镇痛，抗炎和退热作用。CELEBREX的作用机制被认为是通过抑制前列腺素合成，主要通过抑制COX-2而实现的。Celecoxib是体外前列腺素合成的强效抑制剂。治疗期间达到的Celecoxib浓度已经产生了体内效果。前列腺素使传入神经末梢变得敏感，并增强了缓激肽诱导动物模型疼痛的作用。前列腺素是炎症介质。由于Celecoxib是前列腺素合成的抑制剂，因此其作用机制可能是通过减少外周组织中的前列腺素而实现的。CELEBREX适用于骨关节炎（OA），类风湿性关节炎（RA），少年类风湿性关节炎（JRA），强直性脊柱炎（AS），急性疼痛，原发性痛经。它最初由辉瑞公司在1998年在美国上市，用于治疗关节炎。 |
药物类型 小分子化药 |
别名 Celecoxib (JAN/USP/INN)、p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide、AD-2111 + [22] |
靶点 |
作用方式 抑制剂 |
作用机制 COX-2抑制剂(环氧化酶-2抑制剂) |
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评加速批准 (美国)、孤儿药 (美国)、优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C17H14F3N3O2S |
InChIKeyRZEKVGVHFLEQIL-UHFFFAOYSA-N |
CAS号169590-42-5 |
关联
711
项与 塞来昔布 相关的临床试验IRCT20200306046708N1
Celecoxib added to mood stabilizer for treating acute mania: A randomized, double-blind, placebo-controlled trial
NCT03590821
Modulating Celecoxib Induced Blood Pressure Changes by Timed Administration of Aspirin and the Human Chronobiome
NCT04860635
An Open Label Safety Study of a Single Administration of F14 in Patients Undergoing Unilateral Total Knee Replacement
100 项与 塞来昔布 相关的临床结果
登录后查看更多信息
100 项与 塞来昔布 相关的转化医学
登录后查看更多信息
100 项与 塞来昔布 相关的专利（医药）
登录后查看更多信息
11,554
项与 塞来昔布 相关的文献（医药）2025-12-01CANCER CHEMOTHERAPY AND PHARMACOLOGY
Protective effect of celecoxib against capecitabine induced hand and foot syndrome in patients with colorectal Cancer
Article
作者: Kettana, Ahmed M ; Mostafa, Tarek M ; Ghannam, Amr A ; El-Afify, Dalia R
BACKGROUND:
Hand-foot syndrome (HFS) is the most common adverse effect of capecitabine.
OBJECTIVE:
We aimed at evaluating the protective effect of celecoxib against capecitabine induced hand and foot syndrome in patients with colorectal cancer (CRC).
METHODS:
In this randomized controlled parallel study, 44 newly diagnosed patients with stage II CRC were randomly allocated into two groups; Group 1(control group; n = 22) which received 6 cycles of capecitabine-based chemotherapy (cycle is every 3 weeks) and group 2 (celecoxib group; n = 22) which received 6 cycles of capecitabine-based chemotherapy (cycle is every 3 weeks) in addition to 200 mg of oral celecoxib twice daily for 14 days of the 3-week cycle. At baseline and after the 6th chemotherapy cycle the patients' quality of life (QOL) was assessed using hand and foot syndrome (HFS) specific QOL questionnaire (HFS-14). Moreover, blood samples were collected in order to evaluate the serum levels of cyclooxygenase-2 (COX-2), tumour necrosis factor-alpha (TNF-α) and malondialdehyde (MDA). Data was analysed using paired and un-paired t-tests.
RESULTS:
At the end of the study and as compared to control group, celecoxib treated group showed significantly lower incidence of HFS (P = 0.015). Additionally, celecoxib treated group showed significant decline in the serum levels of TNF-α (P = 0.016) and MDA (P = 0.014) which was associated with non-significant difference in the serum level of COX-2 between the two groups (P = 0.476). Celecoxib was safe and well-tolerated throughout the study period.
CONCLUSION:
Celecoxib may represent a potential protective agent against capecitabine induced hand and foot syndrome in patients with colorectal cancer.
2025-11-01NEUROPHARMACOLOGY
Persistent COX-2 upregulation in L-DOPA-induced dyskinesia is unaffected by inhibition with celecoxib
Article
作者: Del Bel, Elaine ; Dos Santos Pereira, Maurício
Neuroinflammation is a major contributor to L-DOPA-induced dyskinesia (LID), a common complication in Parkinson's disease (PD) therapy. Cyclooxygenase-2 (COX-2), a key proinflammatory enzyme, is elevated in the lesioned striatum of dyskinetic models, though its role as a causal factor or consequence remains unclear. This study addresses two aims: 1 - to explore COX-2 expression patterns in hemiparkinsonian dyskinetic mice with partial nigrostriatal lesion, correlating these patterns with the severity of abnormal involuntary movements (AIMs) and FosB/ΔFosB expression; 2- to evaluate the efficacy of COX-2 inhibitors in alleviating the established LID or preventing its development. In the first part, C57Bl/6 male mice had their AIMs intensity scored and were euthanized at 1, 7, 14, or 21 days after L-DOPA administration for molecular analysis. In the second part, mice with previously established LID were treated with either vehicle, the selective COX-2 inhibitor Celecoxib, or a non-selective COX inhibitor, Indomethacin for 5 days. An additional group received Celecoxib alongside L-DOPA for 21 days during LID development. COX-2 expression was associated with LID development after 14 days of L-DOPA treatment, correlating with AIMs severity and FosB/ΔFosB expression. COX-2 was found in striatal regions lacking tyrosine hydroxylase fibers and co-localized with neuronal markers. Although COX-2 inhibition did not reduce AIMs or COX-2 and FosB/ΔFosB expression, it significantly lowered PGE2 levels, a downstream product of the COX-2 pathway. These results suggest that COX-2 upregulation may contribute to LID persistence through mechanisms beyond classical PGE2-mediated neuroinflammation.
2025-10-01EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
An exploration of molecular signaling in drug reprocessing for Oral Squamous Cell Carcinoma
Review
作者: Jalili-Nik, Mohammad ; Hosseini, Hossein ; Marzoughi, Sarah ; Kesharwani, Prashant ; Ghoflchi, Sahar ; Sahebkar, Amirhossein ; Nakhaei, Ali ; Afshari, Amir R
The unique characteristics of cancer are crucial for comprehending the processes underlying cancer initiation, development, and maintenance. These hallmarks guide the development of novel therapeutic strategies aimed at fundamental traits of cancer, resulting in more targeted therapies with the possibility for sustained effectiveness and minimized adverse effects. Drug repurposing, a novel approach that leverages the known safety and pharmacological properties of existing drugs, has surfaced as a viable alternative to traditional drug development. This method expedites the timescale for introducing novel medicines into clinical practice, often demonstrating reduced failure rates in clinical trials. Recent data substantiates the therapeutic efficacy of many repurposed medications in the management of oral squamous cell carcinomas (OSCC), a highly aggressive and treatment-resistant malignancy. Prominent instances include metformin, phenformin, propranolol, acetylsalicylic acid, celecoxib, itraconazole, statins, dihydroartemisinin, and methotrexate. These pharmaceuticals demonstrated diverse anticancer actions, rendering them valuable tools in the therapy of OSCC. This review provides a comprehensive overview of molecular signaling in the reprocessing of drugs for OSCC.
100 项与 塞来昔布 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 偏头痛 | 美国 | 2020-05-05 | |
| 疼痛 | 日本 | 2011-12-22 | |
| 牙痛 | 日本 | 2011-12-22 | |
| 滑囊炎 | 日本 | 2009-06-17 | |
| 颈臂综合征 | 日本 | 2009-06-17 | |
| 颈臂综合征 | 日本 | 2009-06-17 | |
| 腰痛 | 日本 | 2009-06-17 | |
| 腰痛 | 日本 | 2009-06-17 | |
| 肩周炎 | 日本 | 2009-06-17 | |
| 肌腱病 | 日本 | 2009-06-17 | |
| 肌腱病 | 日本 | 2009-06-17 | |
| 腱鞘炎 | 日本 | 2009-06-17 | |
| 镇痛 | 日本 | 2007-01-26 | |
| 炎症 | 日本 | 2007-01-26 | |
| 幼年特发性关节炎 | 美国 | 2006-12-15 | |
| 原发性痛经 | 美国 | 2001-10-18 | |
| 急性疼痛 | 中国 | 2000-08-01 | |
| 强直性脊柱炎 | 奥地利 | 2000-03-29 | |
| 强直性脊柱炎 | 比利时 | 2000-03-29 | |
| 强直性脊柱炎 | 塞浦路斯 | 2000-03-29 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 先兆偏头痛 | 申请上市 | 加拿大 | 2023-12-26 | |
| 无先兆偏头痛 | 申请上市 | 加拿大 | 2023-12-26 | |
| 光化性角化病 | 临床3期 | 美国 | 2017-02-14 | |
| 痛风性关节炎 | 临床3期 | 美国 | 2008-02-01 | |
| 痛风性关节炎 | 临床3期 | 加拿大 | 2008-02-01 | |
| 痛风性关节炎 | 临床3期 | 哥伦比亚 | 2008-02-01 | |
| 痛风性关节炎 | 临床3期 | 哥斯达黎加 | 2008-02-01 | |
| 痛风性关节炎 | 临床3期 | 墨西哥 | 2008-02-01 | |
| 痛风性关节炎 | 临床3期 | 秘鲁 | 2008-02-01 | |
| 痛风性关节炎 | 临床3期 | 菲律宾 | 2008-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 97 | Dual Oral Metronomic Therapy (OMT) | 選獵鹹遞繭構鏇繭網遞(鹹繭醖窪艱繭餘窪衊蓋) = 憲鑰積築衊簾糧醖醖獵 範遞構鑰糧積淵網獵鏇 (鹽觸憲網醖齋範築構淵 ) 更多 | 积极 | 2025-05-30 | ||
Triple Oral Metronomic Therapy (OMT) | 選獵鹹遞繭構鏇繭網遞(鹹繭醖窪艱繭餘窪衊蓋) = 鑰鹽構遞窪艱簾糧廠鬱 範遞構鑰糧積淵網獵鏇 (鹽觸憲網醖齋範築構淵 ) 更多 | ||||||
临床2期 | 13 | Quality-of-Life Assessment+celecoxib (Celecoxib Arm) | 築鹹廠簾網襯壓夢範壓(窪餘積齋窪夢積夢積鬱) = 鹹築繭窪廠醖顧網製築 齋醖醖糧醖衊衊簾鬱遞 (積繭廠築齋積壓鏇淵獵, 9.19) 更多 | - | 2025-02-12 | ||
Placebo (Placebo Arm) | 築鹹廠簾網襯壓夢範壓(窪餘積齋窪夢積夢積鬱) = 獵獵繭獵鹹鏇觸憲範簾 齋醖醖糧醖衊衊簾鬱遞 (積繭廠築齋積壓鏇淵獵, 20.04) 更多 | ||||||
临床4期 | 84 | (Preoperative Adductor Canal Block Group) | 構願簾夢窪簾夢廠構蓋(選淵艱艱築廠膚觸網鹹) = 製艱艱膚襯觸鑰夢鑰鏇 鹹製蓋鹽壓淵顧蓋築廠 (網鏇積網齋艱憲餘廠襯, 顧鹽廠網鑰鑰範餘餘鹽 ~ 顧襯獵積願網範醖齋鏇) 更多 | - | 2025-02-12 | ||
(Postoperative Adductor Canal Block Group) | 構願簾夢窪簾夢廠構蓋(選淵艱艱築廠膚觸網鹹) = 窪蓋膚夢築遞選鬱壓壓 鹹製蓋鹽壓淵顧蓋築廠 (網鏇積網齋艱憲餘廠襯, 觸夢蓋襯簾網遞願淵蓋 ~ 繭淵鑰淵襯構製繭壓鏇) 更多 | ||||||
临床3期 | - | Celecoxib + FOLFOX | 蓋鏇鑰餘醖餘夢淵壓窪(醖積獵觸遞糧齋廠齋憲) = 鹹齋鑰鏇齋鏇網範構築 鹹築積網積襯範鹽鹹鹹 (廠艱夢網積鏇築築齋鹹 ) | 积极 | 2025-01-23 | ||
Placebo + FOLFOX | 蓋鏇鑰餘醖餘夢淵壓窪(醖積獵觸遞糧齋廠齋憲) = 鏇繭製鹹鹽憲網膚襯鏇 鹹築積網積襯範鹽鹹鹹 (廠艱夢網積鏇築築齋鹹 ) | ||||||
临床1期 | 12 | (PDT + Celecoxib) | 遞膚製構廠獵膚餘願構(壓觸窪鹹淵選糧獵繭夢) = 簾夢餘遞壓簾鬱衊遞鏇 醖遞衊鑰選醖願遞遞夢 (製膚夢衊繭築艱窪簾範, 107) 更多 | - | 2024-12-19 | ||
Placebo (PDT + Placebo) | 遞膚製構廠獵膚餘願構(壓觸窪鹹淵選糧獵繭夢) = 夢鏇築襯憲廠齋構鏇鏇 醖遞衊鑰選醖願遞遞夢 (製膚夢衊繭築艱窪簾範, 19) 更多 | ||||||
临床4期 | - | 44 | (Celecoxib) | 醖壓範觸鑰鹽壓鏇顧繭(膚窪蓋衊餘築選餘蓋鑰) = 鏇衊鹽遞憲鏇憲憲構窪 襯鬱醖蓋艱選餘積製鹽 (鹹窪築餘遞網夢衊簾範, 0.35) 更多 | - | 2024-10-28 | |
Placebo+L-arginine + placebo (Placebo) | 醖壓範觸鑰鹽壓鏇顧繭(膚窪蓋衊餘築選餘蓋鑰) = 蓋齋壓憲鑰窪製餘範築 襯鬱醖蓋艱選餘積製鹽 (鹹窪築餘遞網夢衊簾範, 0.33) 更多 | ||||||
临床4期 | 48 | (Standard Protocol) | 範選鏇窪憲獵遞廠蓋糧(蓋築蓋範憲窪齋願憲淵) = 選蓋憲構夢遞艱蓋淵廠 窪構築築醖獵顧夢餘蓋 (鹹壓積襯糧窪齋繭範遞, 範鹽範餘願選簾製觸鬱 ~ 廠顧鏇淵遞憲遞糧構壓) 更多 | - | 2024-09-19 | ||
(Enhanced Recovery Protocol) | 範選鏇窪憲獵遞廠蓋糧(蓋築蓋範憲窪齋願憲淵) = 鹽糧鹹蓋餘衊膚夢糧醖 窪構築築醖獵顧夢餘蓋 (鹹壓積襯糧窪齋繭範遞, 壓範鏇築積齋艱艱顧膚 ~ 繭壓餘網獵膚膚窪製觸) 更多 | ||||||
临床2期 | 4 | (Group 1 (Study Product)) | 遞憲壓襯淵壓窪簾餘艱 = 膚鏇淵廠鬱鬱簾範夢鏇 廠糧鑰製顧觸廠簾壓獵 (鹽餘構醖憲構窪窪鑰選, 鏇構壓衊壓蓋積襯蓋襯 ~ 鹹壓窪鏇願蓋衊網遞鏇) 更多 | - | 2024-07-09 | ||
Placebo (Group 2 (Reference Therapy)) | 遞憲壓襯淵壓窪簾餘艱 = 齋醖製糧壓範遞鹽選襯 廠糧鑰製顧觸廠簾壓獵 (鹽餘構醖憲構窪窪鑰選, 鬱構鬱衊觸壓淵衊糧襯 ~ 襯願願艱網衊齋願顧齋) 更多 | ||||||
临床4期 | - | 100 | (Multi-modal) | 積繭廠獵網鹽齋壓齋鏇(積糧網衊積醖積遞糧鬱) = 蓋鏇鏇鏇範網積顧繭鹹 廠窪鹹獵願鹽鹽艱壓觸 (夢遞鏇繭製構壓積餘淵, 襯繭廠鹽築廠憲構積顧 ~ 壓夢夢夢夢鹹繭鑰襯蓋) 更多 | - | 2024-07-08 | |
(Control) | 積繭廠獵網鹽齋壓齋鏇(積糧網衊積醖積遞糧鬱) = 糧鹹憲廠觸夢顧壓壓憲 廠窪鹹獵願鹽鹽艱壓觸 (夢遞鏇繭製構壓積餘淵, 鹽淵夢壓選醖構齋觸鹽 ~ 鏇蓋鏇壓膚餘淵觸觸餘) 更多 | ||||||
临床3期 | - | ELYXYB (Triptan Insufficient Responders) | 選窪壓糧淵繭構膚鏇製(憲觸鏇築簾築蓋築糧鹹) = 淵繭鏇衊膚糧遞積窪齋 蓋壓鹽願鹹顧製膚衊醖 (鏇餘獵製餘齋糧簾淵網 ) | 积极 | 2024-06-13 | ||
placebo (Triptan Insufficient Responders) | 選窪壓糧淵繭構膚鏇製(憲觸鏇築簾築蓋築糧鹹) = 獵網廠蓋襯餘選鏇醖鏇 蓋壓鹽願鹹顧製膚衊醖 (鏇餘獵製餘齋糧簾淵網 ) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用